Shaanxi Provincial People's Hospital Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Xi'an China (1931)

Organization Overview

First Clinical Trial
2006
NCT00965471
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Bai Jun | Shaanxi Provincial Cancer Hospital | Shaanxi Provincial People's Hospital | Shanxi Provincial Cancer Hospital | Shanxi Provincial People Hospital

Active Ingredients

Drugs in Phase 4 Trials (19)

acetylsalicylic acid (aspirin) (3 trials)

budesonide (rhinocort) (1 trial)

cisatracurium (nimbex) (2 trials)

deng zhan sheng mai (1 trial)

dexmedetomidine (precedex) (3 trials)

eltrombopag (promacta) (1 trial)

etomidate (amidate) (1 trial)

exenatide (byetta) (1 trial)

insulin lispro (humalog) (1 trial)

midazolam (versed) (2 trials)

propofol (diprivan) (4 trials)

rabeprazole (pariet) (1 trial)

remifentanil (ultiva) (2 trials)

sevoflurane (ultane) (3 trials)

sufentanil (2 trials)

thrombopoietin (1 trial)

trimebutine (1 trial)

vecuronium (norcuron) (1 trial)

xingnaojing (1 trial)

Drugs in Phase 3 Trials (7)

allopurinol (zyloprim) (1 trial)

epoetin (Epogen) (1 trial)

febuxostat (uloric) (1 trial)

gefitinib (iressa) (1 trial)

hirudin (1 trial)

thalidomide (Thalomid) (1 trial)

warfarin (coumadin) (1 trial)

Drugs in Phase 2 Trials (9)

almonertinib (1 trial)

anlotinib (1 trial)

carboplatin (paraplatin) (2 trials)

cisplatin (platinol) (1 trial)

etoposide (vepesid) (1 trial)

paclitaxel (taxol) (2 trials)

tislelizumab (1 trial)

trilaciclib (Cosela) (1 trial)

umbilical cord mesenchymal stem cells (1 trial)

Drugs in Phase 1 Trials (2)

berberine (1 trial)

bifidobacterium animalis (1 trial)

Drugs in Other Trials (11)

axitinib (inlyta) (1 trial)

bivalirudin (angiomax) (1 trial)

erythromycin (ilosone) (1 trial)

folic acid (1 trial)

ginseng (1 trial)

heparin (liquaemin) (1 trial)

methylcobalamin (1 trial)

pazopanib (votrient) (1 trial)

pinellia (1 trial)

sodium bicarbonate (1 trial)

sunitinib (sutent) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Injuries (Phase 4)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Cerebral Infarction (Phase 4)

Cerebral Palsy (Phase 3)

Cognitive Dysfunction (Phase 4)

Crohn Disease (Phase 2)

Delirium (Phase 4)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Esophagitis (Phase 4)

Esophagitis, Peptic (Phase 4)

Gastroesophageal Reflux (Phase 4)

Gout (Phase 3)

Hemorrhage (Phase 3)

Intracranial Hemorrhages (Phase 3)

Ischemia (Phase 4)

Leukomalacia, Periventricular (Phase 3)

Lung Neoplasms (Phase 2)

Postoperative Complications (Phase 4)

Premature Birth (Phase 3)

Stroke (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 28
  • # of Trial APIs: 48